Rodin Therapeutics

CEO

• Backed by leading investors, Rodin focused on enhancing synaptic integrity to develop novel therapeutics for neurological disorders
• Acquired by Alkermes plc in November 2019

Teleos Therapeutics

Co-Founder & CEO

• Leveraging an innovative technology platform and unique insights into zebrafish chemical biology to discover novel drug candidates for central nervous system disorders
• With core technology licensed from Massachusetts General Hospital, Teleos was founded in 2013 around strategic partnerships with leading global pharmaceutical companies

Link Medicine

Co-Founder & CEO

• Focused on discovering and developing disease-modifying neurodegenerative therapies
• Over $50 million in equity financing raised from major institutional, strategic and high net-worth individual investors
• Growth from a largely virtual, academic research project to a science-driven, clinical stage company
• Lead program acquired by a large multinational pharmaceutical company

Adam has also served in interim executive and director roles in various emerging companies, and was a principal at Ovation Capital Partners, an early-stage technology venture capital fund based in New York. Prior to his industry experience, he was a member of the corporate finance and private equity groups of leading law firms in Boston, Seattle and New York, where he represented venture capital funds, as well as numerous venture-backed and public companies.